CEACAM5 and neoplasm: Recently, Cox and colleagues evaluated the ability of a humanized anti-CEA antibody (M5A) previously developed by Yazaki [66] and then conjugated it with an 800 nm NIR dye to target GC in orthotopic mouse models, achieving a high tumor-to-background ratio [67,68].